[6/30 held FRONTEO Life Science AI Business Academy] Shionogi-style DX promotion and efforts to address social issues | FRONTEO, Inc. | Providing business solutions with in-house developed AI

[6/30 FRONTEO Life Science AI Business Academy] Promotion of Shionogi-style DX and efforts to address social issues

2023/6/8

【Program】

・Main lecture“Shionogi-style DX promotion and initiatives to address social issues”(Shionogi & Co., Ltd.)

Digital Transformation (DX) is required in the pharmaceutical industry without exception, and it is truly a revolutionary period.Shionogi has formulated a medium-term management plan (STS2030) to transform itself from a conventional R&D-based pharmaceutical company into a "Healthcare as a Service (HaaS)" that creates new added value and solves customer problems. , we are working on new businesses.This time, we will introduce specific examples of initiatives based on our DX strategy.

・'Development of language-based AI medical equipment that FRONTEO is working on (provisional)"(FRONTEO Co., Ltd.)

Click here for registration and seminar details:https://lifescience.fronteo.com/webinar20230630

【Webinar Summary】

Date: 6/30 (Friday) 18:00-19:00

◆ Format: Free web seminar (PC environment with Internet connection is required)

◆ Participation conditions:

We kindly ask that you refrain from applying if you are using a free address, if you are in the same industry as our company, or if you do not know your affiliation.When accessing Zoom on the day, please enter your name and email address that you entered at the time of application in the entry field for Zoom participation.

◆Speakers

Shionogi Pharmaceutical Co., Ltd.
Innovation Fellow, Healthcare Strategy Division
Mr. Hiroyuki Kobayashi

After obtaining a doctorate in pharmacy in March 1999 (Hokkaido University), he joined Professor Dieter Soll at Yale University as a postdoctoral fellow in April of the same year. In 3, he joined Takeda Pharmaceutical Co., Ltd. as a researcher at the Pharmaceutical Research Division, and in 4 transferred to the Axcelead Research Division, which was spun off from the company. In 2001 he joined Shionogi & Co., Ltd. where he is today.
In addition, he is a visiting professor at the University of Tsukuba, an outside director at FloraIndex Co., Ltd., an outside director at AdvanSentinel Co., Ltd., an AMED evaluation committee member, a JST area advisor, a director at the Japan Bioresource Industrial Use Council, and a vice chairman/director at the Japan Sewage Surveillance Association.

FRONTEO Inc.
Life Science AI Business Headquarters Medical Device Team Deputy General Manager
Motoaki Sato

Share this article

0
Facebook
Twitter

<To the previous article

To the next article>

Share this article

0
Facebook
Twitter

Articles in the same category

[Online seminar held on 5/30] Practical techniques for legal due diligence for M&A

[5/31 15th Fraud Countermeasures Study Session] [Must-see for compliance personnel] Mass media response in the event of a crisis

[Online seminar held on 5/9] New framework and practical outlook for European foreign investment regulations - Explanation of the European Commission's new regulation proposal and the regulatory environment of major countries -

[Real seminar held on 4/18] “Crisis management proposed by a competition law/consumer law boutique firm” ~Risk management to avoid a “crisis”~

Exploring patient stratification biomarkers for IgA nephropathy using AI: Overcoming bias with AI

Searching for therapeutic targets for pancreatic cancer - I tried using paper search AI -

Parkinson's disease - Analyzing drug discovery targets using paper search AI

Economic Security Symposium co-hosted by FRONTEO x Moody's Analytics Japan on April 4th

Searching for new targets for sporadic ALS using AI: Become friends with AI